Improving Patient
Outcomes in
Solid Tumor
Cancer TreatmentBIO300
A New Class of Cancer Drug
COVID-19
BIO300
Preventing long term lung damage caused by inflammation
Keeping America Safe
BIO300
Protecting Civilians, First Responders and Our Military
from Nuclear Accidents and Terrorism
Humanetics News
12.16.2022
Humanetics Corporation Presents at the MedInvest Oncology Investor Conference
Read More
11.15.2022
Humanetics Corporation Publishes Results of Phase 1 Trial of BIO 300 Oral Powder in Healthy Volunteers
Read More
10.25.2022
Humanetics Corporation Presents at the 2022 Annual Radiation Research Society Meeting
Read More
10.05.2022
FDA Clears BIO 300 for Studies in Second Oncology Indication
Read More
09.22.2022
Thomas F. Jasper Joins Board at Humanetics
Read More
08.09.2022
Jake R. Nunn Joins Board at Humanetics
Read More
07.27.2022
BIO 300 Pharmacokinetics Data Published
Read More
06.21.2022
US Department of Defense Awards $5.1 Million to Humanetics for Continued Development of Radiation Countermeasure
Read More
05.18.2022
Humanetics Corporation Expands Long-Haul COVID-19 Trial to Additional Sites
Read More
04.26.2022
Humanetics Corporation Publishes New Data Comparing BIO 300 with Neulasta
Read More
04.13.2022
Humanetics Corporation Appoints Mr. Douglas W. Bryce to its Board of Advisors
Read More
09.22.2021
Humanetics Corporation Completes Phase 1 Trial
Read More
10.26.2021
Humanetics Corporation Adds Two New Experts to its Board of Directors
Read More
08.24.2021
Humanetics Corporation's BIO 300 Receives Fast Track Designation from FDA
Read More
06.02.2021
Humanetics Corporation Receives Funding from Regenerative Medicine Minnesota to Study New Drug for Triple Negative Breast Cancer
Read More
01.25.2021
Humanetics Corporation Receives Funding from Department of Defense to Test Drug Against COVID-19
Read More